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Abstract 
Nicotinic receptors are membrane proteins involved in several physiological processes; they are 
considered suitable drug targets for several CNS disorders or conditions, as shown by the large 
number of compounds which entered clinical trials. In recent times non conventional agonists have 
been discovered: positive allosteric modulators, allosteric agonists, site-specific agonists and silent 
desensitizers are compounds able to modulate the receptor interacting at sites different from the 
orthodox one, or to desensitize the receptor without prior opening. If, on one side, these new 
findings further complicate the pharmacology of these proteins and the design and optimization of 
ligands, they indeed offer new opportunities to find drugs for the many therapeutic indications 
















Nicotinic acetylcholine receptors (nAChR) are Ligand Gated Ion Channels (LGIC), members of 
a family called Cys-loop receptors owing to the presence, near the N-terminal extracellular domain, 
of a conserved disulfide bridge between two Cys residues separated by 13 amino acids. These 
proteins have a pentameric structure, being formed by five subunits assembled around a central 
pore. nAChRs are known from more than a century, but only in the last part of 1900 their 
fundamental role in the pathophysiology of the central nervous system has emerged, after cloning 
and expression of the neuronal subtypes [1]. The importance of these proteins as drug targets is 
proven by the high number of compounds which entered clinical trials for several different CNS 
indications; some are listed in Table 1. However, despite all the efforts, the only therapeutic 
application so far is smoking cessation; in many instances, for other diseases or conditions, drugs 
candidates were found endowed with insufficient efficacy and to adverse effects. 
The design of nAChR drugs has been hampered by the complexity of these proteins, and by the 
lack of structural information on the whole channel, which have been obtained only recently [2]. 
Complexity refers, on one side, to the high number of possible subtypes and to the many 
physiological processes in which these proteins are involved; on this topic, which will only be 
partly addressed in this paper, several excellent reviews have been published, to which the reader is 
referred for in-depth information. On the other side, some intriguing properties of the protein itself 
have emerged in recent times, such as the increased numbers of binding sites and their different 
ability to modulate receptor activity, which will be mentioned in this review. If, on one side, this 
complexity may create difficulties in drug design, it also offers several opportunities, yet to be 
exploited.  
 
Subunit composition  
nAChR subtypes consist of five subunits assembled to form a channel. Twelve subunits have 
been cloned from neuronal tissues, classified in nine alpha (α2-α10) and three beta (β2-β4); they 
can be joined into homomeric nAChRs (α7-α9; the α8 subunit has been found in avian but not in 
mammalian tissue) or heteromeric nAChRs, the latter being composed by α(α2-α7) and β(β2-β4) 
subunits or by α9 and α10 [3]. At the neuromuscular junction, the muscle-type nicotinic receptor is 
formed by α1, β1, δ, and γ (fetal) or ε (adult) [1].  
Based on binding studies, the nicotinic receptors can be also classified as sensitive and 
insensitive to α-Bungarotoxin (αBgtx). αBgtx-sensitive receptors contain α7-α10 subunits, but also 
the muscle-type receptor is αBgtx-sensitive. The αBgtx-insensitive receptors are made up by 
combinations of neuronal α and β subunits [4]. More than 90% of these receptor subtypes in rodent 
brain are α4β2* nAChRs1: autoradiographic studies of [3H]-nicotine binding sites in brain showed a 
correspondence with expression pattern for α4 and β2 subunits ([5] and references therein).  
The twelve neuronal subunits can theoretically associate into many combinations, raising the 
number of the possible receptor subtypes; however, it is not known if all possible combinations give 
functional receptors. There is evidence that some particular combinations are more abundant and 
physiologically relevant: for instance, in neurons the α7 subtype is mainly homomeric; the α4β2 
subtype is the most abundant heteromeric subtype in brain from several species; the α3β4 is the 
most expressed at ganglions (see [1], [6] and references therein). In many instances, the initial 











                                                           
screening of new nicotinic ligands, including some of the compounds reported in Table 1, has been 
performed on heterologously expressed homomeric α7 and heteromeric α4β2 subtypes.  
However, the definition of selectivity may change over time due to new experimental findings on 
subunits assembly, among which stoichiometry, which will be discussed later. For instance, it has 
been recently shown that the α7 subunit forms also heteromeric channels: α7 and β2 subunits can 
co-assemble in both heterologously expressed systems and in native brain neurons, showing, with 
respect to homomeric α7 channels, different functional properties and sensitivity to agonists 
(reviewed in [7]). Tissue and subcellular localization, or sensitivity to oligomeric Amiloid-β1-42 
protein (Aβ1–42) are some intriguing properties of this subtype, suggesting a different role with 
respect to homomeric α7 receptors [7, 8].  
Heteromeric receptors may be formed by 2, 3 or 4 different subunits, giving functional 
combinations differing in pharmacological and biophysical properties [4]. It is difficult to study 
these receptors in native tissue, because different combinations can co-localize in the same area [9]. 
Expression in recombinant systems may speed up receptor characterization, and it may help in 
finding new ligands to be used as pharmacological tools to study the receptors in native tissues. For 
instance, the (α3β4)2α5 subtype has been expressed in HEK293 or in CHO cells and a library of 
compounds was tested by means of High Throughput Screening (HTS), disclosing compounds able 
to discriminate between the (α3β4)2α5 and (α3)2(β4)3 subtypes [10, 11]. Also the α6β2β3 has been 
expressed in HEK293 cells and studied by means of HTS; in this case, to overcome problems of 
functional expression, a chimeric α subunit was used, formed by the extracellular domain of α6 
(containing the ACh binding site) and the transmembrane domain of the α3 subunit, and a mutation 
was introduced into the β3 pore-lining region  [12].  
 
nAChR distribution and function 
The α or β subunits are differently expressed in various neuroanatomical regions (Fig. 1). The 
α4β2* receptors are widely distributed throughout the brain; the α7* subtype are also highly 
expressed, particularly in the hippocampus; other subunits have a more restricted localization [1, 4, 
6, 9]. nAChRs may have a pre-, post- and non-synaptic location, accounting for different 
modulating activities on transmission and neuronal excitation. Most of nAChRs have a presynaptic 
localization and modulate the release of both excitatory and inhibitory neurotrasmitters. Therefore, 
the activation of nAChRs can have opposite modulatory effects on the same circuits depending on 
whether they induce the release of excitatory or inhibitory neurotrasmitters [1]. In particular, 
dopamine release is modulated by α4β2*, α3β2* and α6* nAChRs in nigrostriatal terminals [13], 
while presynaptic α7 nAChRs regulate glutamate and GABA release [14]. Presynaptic nAChRs are 
also involved in regulating the release of ACh, serotonin and noradrenaline [15]. 
Nicotinic receptors have roles in synaptic plasticity and development, and participate in 
cognitive processes. Several diseases or conditions have been associated to changes in function or 
expression of nicotinic receptors (see [16] and references therein, and the section on Therapeutic 
potential); some, such as epilepsy or schizophrenia, may have a genetic cause. In many instances 
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Figure 1. nAChR distribution in human brain (modified from ref.[9] with permission) 
 
nAChR modulators  
Nicotinic ligands are usually classified as agonists, antagonists or allosteric modulators; the 
prototypical agonist is nicotine (1, structure in Table 1). Agonists bind to the orthosteric site, fully or 
partially activating the receptor. Competitive antagonists bind at or near the ACh binding site and 
their interaction is mutually exclusive with that of agonists, while pore blockers behaves as non 
competitive antagonists, binding within the channel, thus hindering the ion flow. The majority of 
the compounds which entered clinical trials are full or partial agonists interacting at the orthosteric 
site. The difficulty in designing subtype-selective ligands is due to the high degree of homology 
within the orthosteric sites: several compounds are known which are able to activate or to block 
more than one subtype, or that behave as agonist on one subtype and as antagonist on another.  
Allosteric modulators interact with sites different from those of the neurotransmitter, and affect 
the transition between functional states [16]. Positive allosteric modulators (PAM) increase the 
receptor apparent affinity for the agonist and reduce the concentration required to achieve channel 
opening, while negative allosteric modulators (NAM) behave in the opposite way. The α7 nAChR 
PAMs have been classified as either type I or type II on the basis of a difference in their effect on 
receptor desensitization. Type I PAMs increase the apparent peak amplitude of agonist-evoked 
responses with little effect on desensitization kinetics, whereas type II PAMs reduce desensitization 
and reactivate, to a certain extent, desensitized α7 nAChRs [19].  
Receptor modulation with allosteric ligands is gaining interest because these molecules have the 
potentiality to be more subtype selective than orthosteric modulators, since the neurotransmitter 





have more than one binding site [20]; interaction with those sites may differently modulate 
activation/desensitization mechanisms, which can also affect selectivity. PAMs are also attractive 
molecule because they are able to stimulate the receptor up to a physiological level, their action 
depending upon the concentration of the endogenous agonist; at the same time, this property may be 
a limitation in conditions where the availability of the endogenous agonist is impaired, for instance 
due to neuronal loss. Moreover, the ability of type II α7 PAM to reactivate desensitized α7 
receptors may cause some trouble due to the high calcium permeability of these proteins, which 
may cause calcium overload leading to toxicity [21].  
 
Figure 2. Structure of the Positive Allosteric Modulator PAM-2 (2). 
 
On animal models, several α7 PAMs have demonstrated efficacy in different experimental 
conditions: as an example, compound 2 (PAM-2, Fig. 2), a recently disclosed type II PAM at α7 
receptors, showed procognitive and antidepressant activity in rodents, reduced neuropathic and 
inflammatory pain, and ameliorated ketamine-induced cognitive impairments [22-25]. However, 
two PAMs (3, JNJ-39393406 and 4, AVL-3288, Table I) have entered clinical trials, giving 
contrasting results (see later). Therefore, more work is needed to understand the real therapeutic 
potential of PAMs. 
Silent agonists (Silent desensitizers) 
nAChRs can be desensitized by continuous or repeated exposure to an agonist (e.g. 1), resulting 
in progressive decrease in response to a subsequent stimulus. α4* receptors desensitize slowly after 
exposure to low amount of agonist, but desensitization is long lasting; α7* desensitize after 
exposure to high agonist concentration, but desensitization is readily reversible [26]. 
Receptor desensitization is a conformational transition to a non-conducting agonist-bound state: 
after an initial receptor activation producing an ion current, the system is actually blocked, with the 
channel being in a conformation that has high affinity for agonist [26]. Recently, for the α7 
receptors two different desensitized states have been recognized, obtained under different 
conditions of agonist application, one sensitive and the other insensitive to type II PAM [27]. 
Desensitization has been suggested to play an important role in shaping the effects of nicotinic 
receptor activation, and altered desensitization mechanisms have been associated with some disease 
conditions such as autosomal dominant nocturnal frontal lobe epilepsy, congenital myasthenic 
syndrome and cancer (see ref [28] and references therein).  
Since the consequence of desensitization is a non-conducting state of the receptor, it is not clear 
if agonists produce a particular pharmacological effect actually functioning as inhibitors; indeed, in 
several instances some nAChR antagonists have been shown to evoke agonist-like nicotinic effect 
[29]. In this context, the activity of ligands affecting desensitization in a different way with respect 
to classical agonists, could cast some light. For instance, type II α7-PAMs, as said before, when co-
administered with an agonist (i.e. ACh) reactivate one of the desensitized state of the receptor; 


















Figure 3. Chemical structure of silent agonists 
 
Compounds able to directly desensitize the receptor without prior activation are called “silent 
agonists” or “silent desensitizers”[29, 30]; such behavior has been reported for nicotine (1) at very 
low concentration (10 nM) on α4β2 receptors expressed in HEK293 cells [31], or for 5 (cotinine, 
Fig. 3), a nicotine metabolite, on ganglionic nicotinic receptors in rats [32].  
Recently, silent agonists have been studied mainly on α7 receptors, and an example of such 
compounds is 6 (NS6740, Fig. 3): in vitro characterization revealed a very weak activation (<2%) 
of the α7 receptor, and antagonistic properties toward ACh; agonist-like effect were revealed when 
co-administered with a type II PAM, which reactivate the conducting state, or when tested on a 
slowly-desensitizing mutated receptor [33]. In vivo, this molecule did not improve cognitive 
performance in the mouse passive avoidance test [33], but it blocked the procognitive activity of the 
nicotinic partial agonist BMS-902483 in the mouse novel object recognition test [34]: these findings 
suggest that activation of α7 receptors is an important step in the α7-mediated cognitive 
improvement. On the other hand, 6 is active in different models of chronic (formalin test and 
chronic constrictive nerve injury-induced neuropathy) but not acute pain (tail-flick and hot-plate 
tests) [35]; as well as the α7 antagonist methyllycaconitine (MLA), 6 is able to reduce 
lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) release from microglia [36]. Indeed, 
the α7 nAChR-mediated modulation of TNF-α release has been associated to a desensitized, non-
conductive state of this receptor [37]. 
Silent agonists are ligands binding to the orthosteric site; their pharmacophore should, at least 
partially overlap with that of agonist. Some structure-activity relationships have been derived by 
Papke and coworkers: while the simplest structure activating nicotinic receptor is 
tetramethylammonium, replacing methyl with ethyl groups gave tetraethylammonium, which is 
minimal pharmacophore for α7 silent agonism [38]. In a similar way, by replacing the two methyl 
groups with ethyl moieties, the ganglion stimulating and α7 full agonist 
dimethylphenylpiperazinium iodide (7, DMPP) was transformed into the α7 silent agonist 
diethylphenylpiperazinium (8, DEPP, Fig. 3), whose structure was then further manipulated to 
obtain more potent molecules [39].  
Silent agonists can be either permanently charged compounds or tertiary amines: while amines 
are required to study receptors in the central nervous system, ammonium ions can be used for 
modulating peripheral α7 receptors, for instance in neuropathy and inflammation. Indeed, a 
permanently charged compound, the homopiperazinium derivative 9 (ASM024, Table 1), has 
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Figure 4. Structure of PAMs and allosteric activators.  
 
Recently, allosteric agonists have also been disclosed, i.e. molecules able to directly activate the 
receptor acting at a site different from that of the neurotransmitter. Compound 10 (4BP-TQS, Fig. 
4), a compound structurally related to the type II PAM TQS (11) [40], potentiated the activity of 
ACh when co-administered with 11, showing a type II PAM behavior, but when administered alone, 
it was able to directly activate the α7 receptor. MLA antagonized the effect of 10 in a non 
competitive way, suggesting an interaction on a different binding site, which was confirmed by the 
activity on mutated receptors [41]. Several other analogues have been tested, and some structure-
activity relationships has been derived, showing that small changes in structure can produce a 
different receptor modulation, going from direct activation to positive, negative or silent allosteric 
modulation [42-44]. Interestingly, contrary to ACh and other α7 orthosteric agonists, 10 activated 
the receptor relatively slowly and it did not produce a rapid desensitization, rather a very slow 
desensitization that occurred over a period of minutes [42]. Subtype selectivity was checked on 
recombinant receptors in Xenopus oocytes: 4BP-TQS was able to activate only α7 receptors, but it 
behaved as antagonist on α3β4, α4β2 and muscle-type receptors. In primary rat hippocampal 
neurons, 10 increased calcium influx with micromolar potency, therefore showing activity also on 
native α7 receptors [45]. 
 
Figure 5. Binding sites on the nicotinic receptor. A) Location of the binding site for nicotinic 
activators. The orthosteric binding site is in the extracellular domain, at the subunit interface; 
orthosteric, site-specific and silent agonists bind in this region. The interaction site for the allosteric 
agonist GAT107 seems located nearby, in the vestibule [44]. Positive allosteric modulators bind in a 
region that comprises the gating interface and the transmembrane domain [46]. B) The two different 




































































The binding site of (+)-10 (GAT107, the active enantiomer [47]), has been studied by site-
directed mutagenesis. The two kinds of activity, direct activation and positive allosteric modulation, 
seem to be produced by interaction at two distinct sites: one should be the same transmembrane site 
where PAMs like 12 (PNU-120596, Fig. 4) bind, while the other site, required for direct activation, 
seems to be at the extracellular domain vestibule, in a solvent accessible position (Fig. 5A) [44]. Up 
to now, (+)-10 has been tested in models of acute and chronic pain, being active only on the latters, 
like 6 and also like other α7 agonists and PAMs [35, 48, 49]. Interestingly, in the mouse formaline 
test, the antinociceptive activity of the selective α7 agonist PNU-282987 was found dependent on 
the activation of Peroxisome proliferator-activated receptors α (PPARα), since it was blocked by the 
PPARα antagonist GW6471. However, GW6471 was not effective on the antinociceptive activity of 
12, 6 or (+)-10, suggesting that PPARα activity is involved only when the α7 receptor is activated 
from the orthosteric site [50]. 
 
 
Site specific agonists 
A feature greatly affecting receptor properties is subunit stoichiometry. When expressed in 
recombinant systems, α4 and β2 subunits can co-assemble in two different complexes, formed by 
3α4 and 2β2 or by 2α4 and 3β2 subunits, and characterized, respectively, by low and high 
sensitivity to agonists [51, 52]. This feature is not restricted to this subunit combination, but it has 
been found also for α3β4, α2β2 and α6β2 [53-55]; significantly, there is evidence that combinations 
of α4 and β2 subunits with different stoichiometries exist in the brain [56, 57], possibly associated 
with different modes of transmission or different physiological functions [58]. 
The difference in properties between (α4β2)2β2 and (α4β2)2α4 is due to the presence of an 
additional binding site: the α4/α4 interface, evidenced by means of subunit concatamers with fixed 
arrangement’s order, produces a functional agonist binding site, called unorthodox to differentiate it 
from those (the orthodox ones) at the α4/β2 interfaces (Fig. 5B) [59]. The list of subunits that can 
form unorthodox binding sites comprises α2-6 and β3 (reviewed by Wang [46]), thus including α5 
and β3 subunits which were thought in the past unable to be involved in the formation of functional 
binding sites. 
The number of ACh binding sites have always been related to the number of α subunits, which 
provide the principal component (positive face). For instance, homomeric α7 receptors contain five 
equivalent binding sites: the occupancy of only one is required for maximal activation, while higher 
occupancy increases agonist sensitivity [60]. The unorthodox site represent a third, non equivalent 
agonist binding site on heteromeric receptor, affecting channel properties such conductance, mean 
open lifetime and desensitization [61-64]. Pharmacological properties are also changed: at 
(α4β2)2α4 (the low-sensitive subtype) agonists usually show lower potency (higher EC50 values) 
with respect to (α4β2)2β2 (the high-sensitive subtype). On the other hand, efficacy does not change 
in a similar way: for instance, the efficacy of epibatidine (13) is higher on (α4β2)2α4 than on 
(α4β2)2β2, while the reverse is true for 14 and 15 (respectively TC2559 and sazetidine-A, Fig. 6) 
[59]. This can be explained by the ability of epibatidine to bind to both orthodox and unorthodox 
sites, the latter being responsible for the more efficacious activation. On the contrary, agonists such 
as 14 and 15 are selective toward the α4/β2 site with respect to the α4/α4 one: the low or absent 






















Figure 6. Structure of epibatidine and of site-selective agonists  
 
Agonists are also known, which behave as α4/α4 site-specific modulators [63]. One of such 
compound is 16 (NS9283, Fig. 6), which was initially classified as α4β2 PAM for its potentiating 
activity toward nicotinic agonists in vitro, and in vivo in different models for pain [65-67]; 
subsequent studies showed that it interacts with the α4/α4 binding site [68, 69]. 16 is selective for 
the unorthodox site, with respect to the canonical α4/β2 one, and therefore is able to discriminate 
between the (α4β2)2α4 and (α4β2)2β2 receptors. Unfortunately, it is not selective for the α4/α4 
interface, since it was able to activate also receptors showing unorthodox sites formed by α2/α4, 
α4/α2, α4/α3, α4/α4, α4/α6 subunits, being however inactive on α3/α3, α4/β2, α4/β4 and α7/α7 sites 
[63, 68]. From a structural point of view, 16 is not an allosteric ligand, since it binds to one of the 
ACh binding sites; however, binding only at the accessory site is not enough to activate the receptor 
[63] so the in vivo activity of this molecule depends on the endogenous ACh or on the addition of a 
nicotinic agonist. 16, administered alone, showed pro-cognitive activity in different models of 
cognition [68], and in medial prefrontal cortex it enhanced glutamate release mediated by the 
cholinergic neurons or evoked by low concentration of nicotine [70]. Moreover, co-administration 
with 17 (ABT-594, Table 1) in several animal models potentiate the analgesic activity but not 
adverse effects [67].  
Compound 14 (TC2559, Fig. 6), on the contrary, is a selective modulators for the α4/β2 binding 
site, activating the (α4β2)2β2 receptor but showing very low efficacy at the (α4β2)2α4 subtype [59]. 
In addition, 14 shows in vitro selectivity for α4β2 with respect to other subtypes [71] [72], and 
displays interesting pharmacological properties: it increased dopamine release in rat ventral 
tegmental area (VTA) slices [72] and it showed analgesic activity in different rodent models of pain 
[73, 74]. 14 significantly improved performances of rats in two different cognitive tasks [71] but 
unexpectedly, it suppressed stimulation-induced long-term potentiation (LTP) in rat dentate gyrus, 
an effect that was prevented by the nicotinic antagonist Dihydro-β-erythroidine (DHβE) [75].  
The binding ability of the agonist is dependent on the complementary face of the adjacent 
subunit, as demonstrated for 15 (Fig. 6), 16 and cytisine (18) by site-directed mutagenesis [76]. 
Three residues on the complementary component are hydrophobic (V109, F117, and L119) on β2 
and can interact with the hexynyl group of 15 with higher affinity with respect to the analogous 
residues of the α4 subunit (H114, Q122, and T124), which are hydrophilic. The triple mutation of 
the residues in α4 to resemble β2 gave a receptor with stoichiometry (α4β2)2α4, which can be 












































be. In a similar way, mutation of F117Q in the β2 subunit gave a (α4β2)2β2 receptor which was 
activated by 18, which is ineffective on the wild type. 
These findings may be useful to design site-specific agonists; more work is needed to understand 
if these molecules can be only pharmacological tools to study receptor stoichiometry or may have a 
therapeutic potential. 
 
Figure 7. A) Cation-π interactions established at the agonist binding site, measured by means of the 
nonsense suppression methodology. The cationic nitrogen makes a cation-π interaction (blue) with 
TrpB in the α4β2 receptors; when the nitrogen atom is in a secondary amine, a similar interaction is 
made also with TyrC2. On the α7 receptor, the cation-π interaction is made with TyrC2 and/or with 
a TyrA (red). See also text for explanation. B) Structure of some of the ligands used in these studies  
Structure of the binding site and mode of interaction of nicotinic agonists 
The structure of nicotinic receptor has been extensively studied by means of electron microscopy 
in the last decades of 1900, thanks to the possibility of purifying this protein from Torpedo ray, 
which contains the muscle-type receptor in high quantity, and ending up with a model of the whole 
channel at 4 Å resolution [77]. This was the only structure of the whole channel available up to 
2016, when the crystal structure of the high affinity (α4β2)2β2 receptor was resolved in complex 
with nicotine, in the desensitized form, being the first example of crystal structure of a heteromeric 
pentameric ligand-gated ion channel [2]. This structure revealed important features in the binding 
site and in the overall architecture, which can be compared with other Cys-loop receptors and 
ligand-gated ion channels. Moreover, it allowed also to explore the differences between the binding 
site and the β2/α4 and β2/β2 interfaces, suggesting explanation on why in these locations the 
binding of nicotine is precluded. The structural features emerging from recent crystal structures of 
(α4β2)2β2, the extracellular domain of (α2)5 [78] and of monomeric α9 [79] have been recently 
reviewed [80].   
Until the resolution of the (α4β2)2β2 receptor, the architecture of the orthosteric binding site was 
known from the crystal structure of Lymnaea stagnalis Acetylcholine Binding Protein (AChBP) 
[81] and of several other analogues (reviewed in [82]). AChBP is a structural homologue of the 
extracellular domain of nAChR, the region harboring the ACh binding sites; several nicotinic 
ligands have been shown to bind to AChBPs with high affinity [83]. The discovery of these proteins 
















































homology models of the binding site, but also by exploiting the possibility of co-crystallization and 
by applying fragment-based techniques. As a matter of fact, up to July 2017, in the PDB the number 
of structures of AChBP, alone or in complex with ligands, was higher than 110. Some examples of 
successful strategies can be found in refs [84-88].  
The structure of AChBP in complex with nicotinic ligands provided the first picture of the 
possible arrangement of the binding site, partly suggested from previous studies [89] and later 
confirmed by the structure of the whole channel. The ACh binding site is made by six (A-F) loops: 
A-C are on the principal component (positive side, provided by the α subunit) while D-F on the 
complementary component (negative side, provided by the β subunit, by another α subunit in a 
homomeric receptor, or by the γ or δ subunits in the muscle-type receptor). This description is valid 
for the orthodox site of a heteromeric receptors, while in the unorthodox site both components can 
be given by α and β subunits, depending on the arrangement. Several aromatic residues (the 
aromatic cage, among which are a Trp residue in loop B, and three Tyr residues, one in loop A and 
two in loop C) are present in the active site, and can establish the pivotal π-cation interaction with 
the ammonium group of ACh. Usually, this interaction is made by the TrpB residue. When the 
cationic group is a protonated amine, in the AChBP-1 complex there is an additional interaction 
between the agonist and TrpB, consisting of a H-bond between the NH+ and the backbone CO. The 
other important interaction, as predicted by nicotinic pharmacophoric models (see ref [90] and 
references therein) is the H-bond made by the acceptor group of the ligand (the pyridine nitrogen of 
nicotine or the carbonyl oxygen atom of ACh). In the complex AChBP-1, this H-bond is possible 
thanks to a water molecule, connected to the NH group of a metionine and to the CO moiety of a 
leucine in loopE; these two residue become Asn and Leu, respectively, in the nicotinic receptors, 
and are conserved in all subtypes.  
Although in the recently solved crystal structure of the 1-(α4β2)2β2 receptor complex only the π-
cation interaction is visible, all the three interactions are important in agonist activation, as 
demonstrated by the studies performed by the group of Dougherty and Lester using the nonsense 
suppression methodology [91]. This technique consists in replacing the key residues with unnatural 
amino acids showing lower abilities to be involved in H-bond or π-cation interactions: the potency 
of agonists for activating the mutated receptors, measured by means of electrophysiology and 
compared to wild-type receptor, then shows if that particular interaction is significant for the 
function of the protein. The results strongly support the idea that the contribution of the three 
interactions varies depending on both agonist and receptor subtype (reviewed in [92]).  
Limiting the analysis to the π-cation interaction (Fig. 7), at the muscle-type receptor, ACh and 13 
interact only with TrpB, not with TyrA and TyrC2; on the contrary, and surprisingly, for 1 the π-
cation interaction with TrpB is already weak so that its reduction does not substantially affect 
nicotine potency. At the α4β2 receptor, both ACh and 1 interact strongly with TrpB, and not with the 
other residues of the aromatic cage. However, secondary amines such as 19 (metanicotine), 20 
(nornicotine), 21 (varenicline), and 22 (TC299423, a α6-preferring agonist [93]) establish a 
functional π-cation interaction with both TrpB and TyrC2 [94]. On the α7 subtype, the π-cation 
interaction is formed between ACh and TyrA, and between 13 and both TyrA and TyrC2, but not 
with TrpB. On the α6β2 subtype, the π-cation interaction with TrpB is strong for ACh but not for 1, 
as it happens on the muscle-type receptor, nor for 22 [55]. These findings may give useful hints for 
designing selective nicotinic ligands, providing a structural basis for molecules with particular 














Below we discuss the role of nAChRs in the etiology and treatment of pathologies for which 
nicotinic ligands have reached clinical trials; compound structures are shown in Table 1. 
 
Neurological disorders 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by loss of memory and 
other cognitive functions; the histopathological markers are the presence of neuritic plaques, formed 
by β-amyloid protein (Aβ1-42), and of neurofibrillary tangles, due to hyperphosphorylated tau 
protein. Post-mortem analysis of brains from AD patients showed a large decrease of nAChRs, in 
particular the α4β2* subtype in the cerebral cortex and the α7* subtype in the hippocampus; the 
latter seems to correlate with the severity of cognitive impairment [95]. Aβ1-42 interacts with 
nicotinic receptors [96]. Affinity of Aβ for α7 nAChRs is in the picomolar range and α7 subunits 
are co-localized with Aβ1-42 in senile plaques [97]; heteromeric α7β2 nAChRs were much more 
sensitive to Aβ1-42 inhibition than homomeric α7 nAChRs  [98]. There are some findings 
implicating α4β2 nAChRs in AD: Aβ has inhibitory effects on these and other β2* receptors [99], 
while no co-localization was found between Aβ with α4 subunit [100]. The therapeutic benefits of 
employing  α7 nAChR agonists for AD therapy is due to pro-cognitive effects of  α7 nAChR 
agonists and to the protective role of α7 nAChRs in relation to Aβ1−42 neurotoxicity.  
 However, also α7 antagonists can interfere with nAChR-Aβ interaction [100]. In fact, the 
interruption of α7 nAChR function could be beneficial in the treatment of AD, as demonstrated on a 
transgenic mouse model of AD overexpressing amyloid precursor protein (APP) but lacking the α7 
nAChR gene [101]. At the moment this approach is not pursued: as a matter of fact, the 
compounds that have been tested in clinical trials act as full or partial agonists at α4β2 (23-25) and 
α7 (26-30) receptors, or show a dual α7 and α4β2 activity (21 and 31, Table 1). The compounds 
tested so far had limited success: only EVP6124 (26) seems effective in improving cognitive 
performance in patients with mild-to-moderate AD [102]. 
An AD-like pathology also occurs in adults with Down’s syndrome, in the third decade and 
beyond. The production and deposition of amyloidogenic Aβ peptides are faster due to the extra 
copy of the APP gene on chromosome 21 [103]. α7 nAChR modulation has been proposed as 
treatment [104] but presently, only the non-selective agonist nicotine (1) is being tested in a phase 
1-2 clinical trial.  
Parkinson’s disease (PD), characterized by a prominent decline in the nigrostriatal dopaminergic 
pathway, is characterized also by a pronounced decline in AChR expression in the cerebral cortex of 
PD patients [105]. The decline is particularly evident in α6β2* nAChRs, smaller in the α4β2* 
receptor subtype while there is no change in α7 receptor expression. The explanation may be due to 
the diverse localization of these subtypes in this tissue: α6β2* nAChRs are primarily located on 
incoming dopaminergic afferents, while α7 are positioned on non-dopaminergic terminals, and 
α4β2* are on dopaminergic, GABAergic and serotoninergic neurons [106]. The cholinergic and 
dopaminergic systems are closely connected, and this finding supports the hypothesis that nAChR 
drugs may be useful for PD therapy, also because nicotine facilitates dopamine release on 












Commento [N4]: nAChR?? Oppure in 
generale colinergici 





with PD [107] and the lower risk to contract the disease depends on smoking duration, intensity and 
how recent is cessation. Nicotinic ligands which entered clinical trials are 21 (varenicline), 30 
(AQW051) and nicotine, tested for treatment of excessive daytime sleepiness, of gait and balance 
impairment, and of levodopa-induced dyskinesia.  
 
Psychiatric diseases and neurodevelopmental disorders 
Schizophrenia is a neurodevelopmental disorder which shows symptoms that can be classified as 
positive, negative or cognitive. The high percentage of smokers among schizophrenic patients, the 
positive effect of nicotine on cognitive processes, and other evidences (reviewed in [108]) have 
suggested the modulation of α7 receptor as possible therapeutic intervention. As seen in AD, also in 
brains from schizophrenic patients α7 nAChR protein expression is decreased in different 
percentage according to the cortex region (frontal, parietal and dorsolateral prefrontal) [109, 110]. 
Although there are less biological data linking the α4β2 nAChR to schizophrenia, this receptor has 
also been targeted for the treatment of cognitive impairments associated with this disease [16]. 
Recently the systemic administration of type II α7 and α4β2 nAChR PAMs has been suggested for 
the treatment of central nervous system disorders and in particular for schizophrenia [58, 111]. At 
present, indeed α7* nAChR agonists and PAMs appear to be the most effective hope for the 
treatment of schizophrenia: the amelioration of cognitive deficits is important for improving 
negative symptoms and the quality of life, also because the antipsychotic medication has a slight 
effect on cognitive symptoms in schizophrenic patients.  
Several α7 agonists (26-31) and PAM (3, 4) entered clinical trials. Some interesting result were 
found for 28, 29 and 31, especially on negative symptoms. Clinical trials on PAMs gave contrasting 
results: compound 3 (JNJ-39393406), a type II α7-PAM developed at Janssen Pharmaceutical, was 
tested on regularly smoking male patients with schizophrenia, but failed to reverse basic deficits of 
information processing [112]. A Phase 1 trial on healthy subject for 4 (AVL-3288, a type I α7-
PAM), showed indications of positive although non-significant effects on cognition, which need to 
be confirmed in Phase 2 trials [113]. Varenicline, partial agonist for the α4β2 nAChRs and full 
agonist for the α7 nAChRs, improves cognition in schizophrenic patients [114, 115]. Also 23 
(AZD-3480, α4β2 partial agonist), and nicotine, have completed clinical trials, but with 
disappointing results (Table 1). 
Depression is a severe psychological condition that is usually treated with antidepressants drugs 
that target monoamine transporters regulating the uptake of neurotrasmitters (dopamine, serotonin 
and norepinephrine). The hypothesis that there is a cholinergic hypertone in major depression is an 
old theory [116], supported by new studies on animals and humans. In fact, using magnetic 
resonance imaging studies, levels of choline were shown to be increased in the brains of patients 
with depression, and choline levels have been related to alterations in cholinergic function [117]. 
Moreover, physostigmine, an acetylcholinesterase inhibitor that potentiates cholinergic 
transmission, produced depressive-like symptoms [116], while the administration of α7 or α4β2 
nicotinic antagonists, or compounds that induce desensitization, reduced depressive symptoms [95]. 
SPECT (single photon emission computed tomography) and PET (positron emission tomography) 
studies using α4β2* nAChR specific radioligands, revealed that, across all brain regions, the β2* 
nAChR availability in depressed patients or in PD patients with depressive symptoms was lower 
than that in healthy subjects [118, 119]. In general, the inhibition of nAChR activity is beneficial in 




















citalopram and reboxetine. Antagonists alone also shown antidepressant-like effects in several 
animal models suggesting that inhibition of nAChR function through processes such as 
desensitization also contributes to antidepressant efficacy [120]. However, in two phase 3 clinical 
trials, TC-5214 [(S)-32] was tested as adjunct therapy in patients with depression but did not show 
efficacy [121]. On the contrary, Varenicline, tested as smoking cessation agent in patients suffering 
or having suffered from depression, did not exacerbated the disease [44][Anthenelli, 2013 #1185. 
Trials with nicotine are on-going. 
Neurodevelopmental disorders such as autism spectrum disorder (ASD) and attention deficit 
hyperactivity disorder (ADHD), although most commonly considered in childhood, can be lifelong 
conditions. ASD is characterized by deficits in social interaction, stereotypic behavior, difficulties in 
verbal and non-verbal communication and by cognitive impairment. nAChR alterations are 
correlated to autism, in particular a reduced expression of both α4 and β2 subunits was observed in 
frontal, parietal and cerebellar cortex but no in thalamus [Martin-Ruiz, 2004 #1139]. α4β2 nAChR 
loss results from an impaired post-translational mechanism regulating its expression, since there is 
no reduction in mRNA expression [122]. In contrast to the loss of α4 and β2 subunits, there is a 
compensatory increase in the expression of the α7 subunit. The alterations in AChRs in ASD may 
also serve as an early molecular biomarker: the monitoring, by means of PET, of α4β2 nAChR 
levels in the frontal, parietal and cerebellar cortex might provide a clinical tool to assess the 
effectiveness of pharmacotherapies for autism [123]. The extensive loss of α4β2 nAChRs provides 
a rationale for drugs that can upregulate and activate α4β2 nAChRs: agonists and PAMs for this 
subtype can help to restore its levels of expression and may be beneficial in correcting deficits of 
ASD. So far, however, only α4β2 antagonists like mecamylamine 32 has been tested in clinical 
trials, with negative results [124], while the trial on nicotine is ongoing (Table1). 
ADHD is the most common psychiatric disorder of childhood. ADHD was classically attributed 
to dysregulation of the catecholamine system, but the positive effects of cholinergic agonists on 
attention and memory have led pharmaceutical companies to explore the utility of nicotinic agonists 
for ADHD treatment. In this context, the α4β2 subtype seems to be of particular importance [125] 
even if the main challenge to progress in ADHD treatment remains the lack of knowledge of the 
causes of the disease. Several α4β2 (23-25, 33) and α7 agonists (27, 31) underwent clinical trials 
(Table 1). Promising results have been achieved for ispronicline (AZD3480, 23) [126] and ABT894 
(33) [127] but not for 24, 25 and 27 [128, 129] (Table 1).  
 
Pain and inflammation 
Since many years the nicotinic receptors have emerged as interesting drug targets for pain 
treatment [130]. More than 20 years ago the analgesic properties of epibatidine (13) [131] were 
discovered; since 13 is a potent agonist at α4β2* receptors, even if not selective, research has been 
initially focused on this subtype, and several potent α4β2 full agonists have been synthesized. 
These compounds, among which are ABT-594 (17) and TC2629 (36), are endowed with strong 
analgesic properties, but a narrow therapeutic window [48, 132]. ABT594 was tested in a phase 2 
clinical trial, showing efficacy but limited tolerability due to side effects [133]. Even though 
research is very active in this field, only the α4β2 agonist ABT-894 (33) has completed a phase 2 
clinical trial for diabetic neuropathic pain, not confirming the results of 17 [134]. Interestingly, as 
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α4/α4 site-selective ligand NS9283 (16), suggesting the combination of a α4β2 full agonist and a 
α4β2 selective potentiator as new therapeutic strategy [67]  
It is known from long time also that α7 stimulation produces antinociceptive activity [135]. 
However, the development of α7 agonists may not be a priority given that a long-term treatment 
can lead to receptor desensitization and/or inactivation, suggesting possible adaptations to their 
effects after chronic use [136]. More recently,  α7 type II PAMs and silent agonists have been 
evaluated in preclinical models for pain [35, 49], confirming that α7 nAChR modulators can be an 
attractive and versatile alternative to α4β2 agonists. 
Besides the α4β2* and α7* receptors, other nAChRs are also known to be involved in pain. In 
particular, the α5 subunit plays a significant role in nociception and the α4β2α5* subtype may be 
the target for nicotinic analgesic agents [137]. Furthermore, dorsal root ganglion neurons coexpress 
the α9 and α10 nAChR subunits, suggesting a role for the α9/α10 nAChRs in pain processing 
[138]. This was supported by a recent study showing that RgIA4, a peptide showing highly 
selectivity and potent inhibition of the α9α10 nAChR subtype, prevented chemotherapy-induced 
neuropathic pain in rats [139].  
Inflammatory states normally produce pain, and the α7 receptor plays an important role also in 
the cholinergic control of inflammation, regulating the production of pro-inflammatory cytokine 
through neuronal and non-neuronal mechanisms [140, 141]. Recently it has been reported that the 
activation of α7 nAChRs on nonneuronal cells, like macrophages, efficiently suppressed TNF-α 
synthesis [142]; high TNF-α levels are involved in delaying diabetic wound healing through an 
excessive fibroblast apoptosis and reduced fibroblast density [143]. The selective α7 nAChR 
agonist PNU282987 (Fig. 8) significantly reduced the TNF-α level of wounds in a murine model, 
by inhibiting its production through activation of α7 nAChR on macrophages, and accelerated the 
healing process. So far, only ATG002 (a nicotine-based gel) has been tested for diabetic foot ulcer 
in a clinical trial (Table 1). However, as said before, also modulation of α7 receptors by means of 
silent agonists reduced TNF-α release, supporting the hypothesis that this action is associated to a 
desensitized, non-conductive state of this receptor [37].  
Also chronic inflammatory diseases of the airways, like allergic and non-allergic asthma, can be 
treated with α7 agonists. Administration of α7 nAChR agonists significantly attenuates the 
development and function of innate lymphoid cells (ILCs) and in particular group 2 ILCs  (ILC2s), 
abolishing both airway hyper-reactivity (AHR) and allergic inflammation. Therefore, the 
cholinergic pathways have a protective role in the pathogenesis of asthma, and α7 nAChR agonists 
can be useful for the treatment of ILC2-mediated asthma [144]. The α7 modulator TC6987 (34) and 
the α7 silent agonist 9 [145] have completed clinical trials in moderate and allergic asthma; the 
latter did not show efficacy [146]. 
 
Food behavior  
The involvement of nAChRs in food intake behaviors, in regulating body weight, in energy 
homeostasis and physical activity, is due to central and peripheral sites of action. One mechanism 
proposed for the nicotine-induced reduction of appetite and body weight is an increased activity of 
α3β4*, α7 and α4β2 nicotinic receptors in pro-opiomelanocortin (POMC) neurons of the 
hypothalamus, resulting in stimulation of the melanocortin system [147]. A primary potential 
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Cholinergic innervations are abundant in the hypothalamus, and there are high levels of α7 nAChR 
expression, leading to activation of POMC neurons. Another mechanism proposed is that a long-
term sugar consumption causes an imbalance in expression of dopamine D1, D2 and D3 receptors 
and of α4β2* and α6β2* nAChRs in nucleus accumbens (NAc) [148], a change similar to that 
observed for addiction to substances of abuse [149]. Therefore, targeting the α7 nAChRs may be a 
useful therapeutic strategy to treat and manage obesity: GTS-21 (31) is in phase 1 clinical trial for 
this indication. The α4β2 partial agonist and α7 full agonist varenicline reduces sugar consumption; 
it is in a phase 3 clinical trial for controlling weight gain after stopping smoking. In mice, constant 
infusion of sazetidine-A (15) decreased food intake robustly and body weight; the proposed 
mechanism is desensitization of α4β2* subtype [147].  
Recently, it has been reported that the regulation of glucose and energy homeostasis may be due 
to nAChRs in nonneuronal cells. Mice pancreatic islets present a predominant expression of α7 and 
β2 nAChR subunits but at lower levels than in the CNS, while α5 and β2 nAChR subunits are 
prevalent in human islets. Double α7 and β2 deficiency mice shows increased spontaneous physical 
activity, no change in body weight though associated with a modification of body composition with 
increased lean and bone mass and decreased fat pads [150]. Compound 34 (TC-6987), an α7 
modulator, has been studied in phase 2 clinical trial for the treatment of type 2 diabetes mellitus.  
 
Substance of abuse 
nAChRs are important pharmacological targets for the development of medications to treat 
alcohol and drug dependence. The drugs approved for smoking cessation are the α4β2 partial 
agonists varenicline (21, approved by FDA) and cytisine (18, approved in Europe) and bupropion 
(35, approved by FDA), behaving as α3β2/α4β2 antagonist [151]. Nicotinic ligands like the α4β2 
agonists ABT-089(24) and dianicline (37), and the association of 21 and 35 have been studied in 
phase 2/3 clinical trials for smoking cessation. Dianicline did not show efficacy beyond the initial 
treatments [152]; with respect to 21 alone, the association between 21 and 35 was more effective in 
the initial treatment phase but not after longer times [153, 154]. Recently the involvement of α7 and 
α6β2* have been investigated and there is preclinical evidence that inhibition of α6β2* and 
activation of α7 can be novel therapeutic strategies with a significant decreases in motivation to 
self-administer nicotine [155]. In animal models selective α6 antagonists were effective in reducing 
nicotine self-administration (see [151] and references therein); these substances should have less 
side effects compared to the non-selective antagonist mecamylamine, since the localization of α6* 
receptors is more restricted. Mecamylamine has been extensively tested in clinical trials for 
smoking cessation yielding contrasting results [156, 157]. GTS-21, with a dual α7 agonist and 
α4β2 antagonist activity, is undergoing a phase 2 clinical trial for tobacco use disorder, while the 
trial involving the α7 agonist EVP-6124 (26) has been terminated. 
Regarding other drug dependence, nAChR antagonists were found to decrease cocaine self-
administration [158] and to have a critical role in regulating the rewarding effects of cannabinoids 
[159]. Alcohol dependence can be treated with α4β2 partial agonists such as cytisine  (18) and 
varenicline (21); the latter was found efficacious in reducing alcohol drinking in both animals 
models and humans. Also sazetidine-A (15) was able to reduce alcohol drinking in alcohol-
preferring rats [160]. A phase 3 clinical trial on mecamylamine did not show significant effects on 























Nicotinic acetylcholine receptors are expressed also in cancer cells and contribute to the 
development and progression of cancers either directly, through the activity of nicotine and its 
derived carcinogenic nitrosamines, or indirectly through the deregulation of the nAChRs. Chronic 
exposure to nicotine or nicotine-derived carcinogenic nitrosamines upregulates α7 and α9 nAChRs 
and desensitizes α4β2 nAChRs, leading to activation of oncogenic pathways, to promotion of tumor 
angiogenesis and inhibition of apoptosis in multiple types of cancers [162]. The α7* and α4β2* 
receptors differently regulate the release of neurotransmitters which have opposite actions on cell 
proliferation; it has been proposed that unbalance between the activity of these two receptors affects 
cancer growth in smokers [163]. The tobacco-specific carcinogenic nitrosamines, NNK and NNN 
(Fig. 8) interact with nAChRs: NNK was found to bind with high affinity to α7 receptors and to 
stimulate Small Cells Lung Cancer (SCLC) cells proliferation, an effect which was antagonized by 
α-Bgtx suggesting α7 activation [164]. On α4β2 receptors, NNK behaved as a partial agonist, while 
NNN was an antagonist [165]. Several evidences suggest that α7 antagonists may be useful to block 
cancer cells proliferation, but their use in vivo could be problematic, considering the physiological 
processes in which α7 receptor activation is involved. On the contrary, α7 nAChR stimulation 
protects neurons from oxaliplatin toxicity through an astrocyte-mediated mechanism [166]. Both 
varenicline and nicotine have been tested in cancer patients, but only for smoking cessation, 
because smokers have higher risk of treatment complications with respect to non-smokers. 
In cancer patients, during and following chemotherapy, cognitive deficits referred as “chemo-
brain” may appear. The study of “chemo-brain” is complicated by the difficulties to have animal 
models [167], and currently there is no approved treatment for this indication. At present, 
transdermal nicotine is studied in a phase 2 clinical trial for the treatment of chemo-brain in patients 
who are 1-5 years post-chemotherapy. 
 
Figure 8. Structure of PNU282987 and of carcinogenic nicotinic nitrosamines 
 
Conclusions and future directions 
One of the main achievement in the last ten years of research on nicotinic receptors is the 
discovery of compounds able to modulate nAChRs through different sites, either allosteric or 
orthosteric; this is important for different reasons. First, modulation from allosteric sites should 
allow, in principle, to achieve the subtype selectivity which has been difficult to obtain with 
orthosteric ligands, and which has been among the reasons for failure in clinical trials. Second, 
PAMs may represent for the nicotinic receptors what benzodiazepine have been for GABA-A 
receptor, i.e. the possibility to activate the receptor without exceeding the maximal physiological 
level of the tissue. Third, compounds affecting desensitization in different way give the opportunity 
to study the contribution of this mechanisms in the activity of the receptor. Fourth, the multiplicity 
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receptor with similar subunits but in different stoichiometry. The medicinal chemists therefore have 
the possibility to exploit these different druggable sites to design new ligands. 
The challenges for the future are, however, numerous. Selectivity still may be the highest 
obstacle to overcome. In this regard a great help may come from structural studies: it is likely that 
in the near future other crystal structures of nicotinic receptors will become available, giving a close 
picture of different subunit interfaces. Optimization of PAMs is important but it may not be 
straightforward, since they do not show a general pharmacophore: PAMs have been discovered by 
means of HTS techniques using different libraries of compounds, and may bind to more than one 
site, so giving multiple structure-activity relationships. Allosteric activators are a promising new 
class of nicotinic modulators, but unfortunately at present only compounds showing dual agonistic-
PAM activity are available: it will be necessary to disclose in the future “pure” allosteric agonists to 
understand the consequence of receptor activation by this mechanism. Last, but not least, 
optimization of potency and selectivity and careful preclinical and clinical investigations will clarify 
if silent desensitizers, site-selective agonists, PAMs and allosteric agonists could be compounds 
useful only as pharmacological  tools, or if they really possess a therapeutic potential, exploitable 





Table 1. Nicotinic agents that are or have been studied in clinical trials by U.S. National Institutes 
of Healtha. 
  
Drug Action on 
nAChR 













Down syndrome; 1,2 (R)  
Mild Cognitive Impairment; 1,2 
(R)  
Parkinson’s disease; 1,2 (C)  
Major depressive disorder; 4 (R)  
ASD; 1 (R)  
Chemo Brain; 2 (R)  
Schizophrenia; d 
 
Low or medium doses of nicotine 
i.v. did not alter symptoms of 
schizophrenia or attention [168] 
Modest improvement of nicotine 
on attention, not in other cognitive 
functions, in smoking but not in 













α7 PAM Schizophrenia,  Smoking cessation in schizophrenia; 2 
Failed to reverse basic deficits of 





















No significant inhibition of 
allergen-induced asthmatic 
response and related airway 
inflammation. Side effect: cough. 
[146] 








Diabetic neuropathic pain; 2 
 
 Significant efficacy in the 
treatment of  diabetic peripheral 
neuropathic pain. Side effects: 
nausea, dizziness, vomiting, 








α4β2  Partial 
Agonist; α7  
Agonist 
Nicotine dependence in 
depression; 4 
Increase in smoking cessation in 
smokers with current or past 
depression without exacerbation of 
depression or anxiety.  [170] 
Schizophrenia; 3 
 
Cognitive improvements as 
adjunctive treatment with 
antipsychotics. Side effects: 









Alzheimer’s disease; 2 
 
No improvement of cognition in 
korean patients with mild-to-
moderate Alzheimer's disease. 
Side effects: gastrointestinal. [171] 
Parkinson’s disease; 2,4 (R, A)  
Obesity; 2,3  (R)  
Alcohol use disorder; d 
 
Inhibition of alcohol consumption 
in a population of heavy drinkers. 
[172] 
Methamphetamine Dependence; 1 
Significant improvement of 
reaction time on the n-back for 
visual stimuli in METH-dependent 
volunteers. [173] 
Cocaine dependence; 2 (C)  
Smoking cessation in 
schizophrenia; 3 
 
Significant efficacy in smoking 
reduction in people with 
schizophrenia. [174] 












Significant improvement of 
cognitive and clinical ADHD 
symptoms. Dose: 50 mg. [126] 
Schizophrenia; 2 
 
No efficacy. Psychiatric side 
effects recorded. [175] 
Alzheimer’s disease; 2 









Nicotine addiction; 2 (T)  
Alzheimer’s disease; 2 (T)  
ADHD; 2 
 
Effective in a pilot study but non 
on a larger trial. [128] 










-; 1 Side effects: nausea, headache and dizziness [177] 
ADHD; 2 
 
No significant improvements of 
ADHD symptoms after 2 weeks of 
treatment . [129] 
Alzheimer’s disease; 2 (C)  











Positive effect on cognitive 
functions in patients treated with 
antipsychotic drugs. [178] 
Alzheimer’s disease; 2b 
 
(At 28 showed improved cognitive 
performance with respect to 
placebo. Dose: 2 mg/die. [102] 









α7  Agonist 
Schizophrenia; 2 
 
The positive results of exploratory 
study were not confirmed in larger 
trials. [179] 
Alzheimer’s disease ; 1 Discontinued 
[http://adisinsight.springer.com/dr
ugs/800026693] 
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Lack of a consistent effect on 
cognition in non-smoking subjects 
with schizophrenia; positive effect 
on negative symptoms. [180, 181] 
Alzheimer’s disease; 2b 
 
No significant improvement in 
subjects with mild-to-moderate 
AD, alone or with AChEI. Side 
effects: agitation, constipation, 
diarrhea, fall, headache. [182, 183] 







Alzheimer’s disease; 2 (C)  
Schizophrenia; 2 
 
No improvement of cognitive 
deficits but improvement of 











Following treatment with 32, brain 
activation, measured by means of 
fNMRI, was not associated with 
changes in cognitive performance. 
[185] 
Levodopa-induced Dyskinesia in 
Parkinson’s Disease;  2  
No significant reduction of 
dyskinesia or parkinsonian 
severity. [186] 
Alzheimer’s disease; 2 (T)  







agonist  and 
α4β2 
antagonist 
ADHD; 2 (C)  
Alzheimer’s disease; 2 (C)  
Schizophrenia; 2 
Significant effects on 
attention/vigilance  
and working memory; 
improvement of negative 
symptoms. [108] 
Tobacco use disorder; 2 (A)  








Antagonist Major depressive disorder; 3 
No efficacy was shown in patients 
with inadequate response to prior 
antidepressant therapy. Side 
effects: constipation, dizziness, dry 









Cognition in schizophrenia; d 
Worsening of performance relative 
to placebo and varenicline, to a 
greater extent in participants with 
schizophrenia than in healthy 
controls. [188] 
Alcohol dependence; 2 
 
No significant effect on alcohol 
consumption in patients with 
alcohol use disorders. [161] 
Autism; 1 No significant benefit was suggested. [124] 
Smoking cessation; 2 
No evidence of efficacy as 
adjuvant with nicotine-
replacement therapy. [156] 








Diabetic neuropathic pain; 2 
 




Significant reduction of ADHD 
symptoms in adults. Dose: 4 mg 
BID. Side effects: nausea, 
dizziness, headache, and fatigue. 
[127] 
Commento [u15]: 2b ?? 
21 
 









α7 agonist; f  
open channel 
stabilizer g 
Asthma; 2 (C)  
Type 2 diabetes mellitus; 2 (C)  













Smoking cessation; 3 
 
Combined use of 21 and 35, 
compared with 21 alone, increased 
prolonged abstinence at 12 and 26 
weeks but not at 52 weeks. Side 
effects: Anxiety and depressive 
symptoms. [154] 
Higher efficacy, after 12 weeks 
treatment, in patients not 
responding to prequit nicotine 
patch treatment. [153] 
Alcohol use disorder; 2 (A)  






Agonist Pain; 2 
In Postoperative Dental Pain the 










α4β2  Partial 
Agonist Smoking cessation; 3 
No efficacy for smoking cessation 
beyond the initial treatment phase. 
Side effects: diarrhea, nausea. 
[152] 
ATG002h Agonist Diabetic foot ulcers; 1,2 (T)  
a http://clinicaltrials.gov, by U.S. National Institutes of health; b C: Completed; A: Active, R: Recruiting; T: Terminated; 
U: Unknown;  c. Information were taken from peer-reviewed papers or from Web news. d Phase non reported;  e From ref 
[133]; f Retrieved from ref. [189189]. g Definition reported on www.clinicaltrial.gov (NCT01293669).   h Low-dose 
Nicotine gel, NCT00316537.  
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Executive summary 
• Nicotinic receptors are pentameric membrane proteins; twelve neuronal subunits have been 
cloned, which can theoretically associate into many combinations, raising the number of the 
possible receptor subtypes and. making the design of selective ligands difficult.  
• Nicotinic receptors are modulated by compounds interacting at orthosteric or allosteric sites, 
located in the extracellular domain or in the transmembrane region. Orthosteric ligands can act 








discriminate among receptor subtypes made up by the same subunits but with different 
stoichiometry. 
• Agonists activate and desensitize the receptors; silent agonists block the receptor in the 
desensitize state without prior activation. Positive allosteric modulators potentiate the agonist 
activity and reactivate the desensitized receptor. 
• Nicotinic receptors are involved in many different physiological and pathological processes, 
and therefore are important drug targets for several disorders or conditions 
• Careful preclinical and clinical investigations are necessary to discover the therapeutic 
usefulness of non-conventional nicotinic receptor modulators.  
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